News

UK Neuroscience Professor Greg Gerhardt's new research program will provide answers to questions about the role of neurotransmitters in the progression of Alzheimer’s disease.

The discovery could yield a key insight which could have broad implications for understanding neurological changes associated with aging.

Goldstein also is co-director of the Kentucky Neuroscience Institute, co-director of the UK Neuroscience Research Priority Area and interim director of the UK-Norton Healthcare Stroke Care Network. Goldstein’s two-year term on the board of directors begins later this month.

Hyperbaric oxygen treatment (HBO) is a treatment that is now being experimentally studied in adult patients with severe traumatic brain injuries (TBI). Hyperbaric oxygen treatment is a specialized way, using a pressure chamber, to dramatically increase the amount of oxygen delivered to body tissues.

Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.

A $2.9 million grant from the NIH is supporting a multidisciplinary team of UK researchers in continuing their work to find therapeutic strategies to resolve neurovascular inflammation and repair blood-brain barrier dysfunction in epilepsy.

In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.

Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.